Open AccessErlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
Author(s) -
С. В. Орлов,
Alexandra M. Lozhkina,
Svetlana Odintsova,
М. А. Свириденко,
Antonina O. Cheremnykh,
Margarita Urtenova,
Е. А. Филиппова
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-10-64-71
Subject(s) - erlotinib , bevacizumab , medicine , tolerability , lung cancer , oncology , adenocarcinoma , chemotherapy , gene mutation , epidermal growth factor receptor , mutation , gene , cancer , adverse effect , biology , biochemistry
The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted drug – VEGF inhibitor – Bevacizumab, are shown. A clinical case of EGFR-positive NSCLC and its treatment with erlotinib was considered. Ways of overcoming resistance to treatment are studied. The use of erlotinib should be considered as one of the standard methods of first and subsequent therapy in patients with NSCLC in later stages with confirmed mutations of the EGFR gene.